Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / VPT:CC - Ventripoint AI Heart Imaging Technology To Be Presented at British Society of Echocardiography Annual Conference


VPT:CC - Ventripoint AI Heart Imaging Technology To Be Presented at British Society of Echocardiography Annual Conference

(TheNewswire)

Toronto, Ontario – The Newswire –October 12, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) hasbeen accepted as a lead sponsor at the British Society ofEchocardiography’s (BSEcho) annual conference to demonstrate its useof Artificial Intelligence to create MRI-quality model of the heartfrom ultrasound images.

The highly anticipated hybrid conference in Cardiff, UKwill bring together renowned experts and professionals in the field ofechocardiography from Oct. 13 th to 14 th . The BSEcho isthe leading global forum for the study and advancement of ultrasoundimaging and Doppler techniques in cardiology.

“We continue to place Ventripoint’s AI technologybefore the world’s leaders in the treatment of cardiovasculardisease,” said Ventripoint President & CEO, Dr. Avira Macanovic.“This is an elite audience that will appreciate our ability to turnultrasound images into a MRI-quality model of the heart, at a speedand cost never before possible.”

Some of the topics discussed this year at the BSEchowill the use of AI in routine scans, LV functional assessment,musculoskeletal health, stress echocardiography, and much more.

As a gold sponsor, Ventripoint Diagnostics will have aprominent presence at the BSEcho  Conference with an interactivebooth in the main hall. The booth will give attendees an opportunityto learn about the VMS+ 3.0 system, engage in hands-on demonstrations,and interact with the Ventripoint team to gain deeper insights intothe technology and clinical applications.  Ventripoint will also havedesignated sponsorship activities such as direct emails to members,social media broadcasts, and inclusion to Echo eNews.

This is the second year that Ventripoint has beenhighlighted in the meeting, demonstrating its commitment to advancingcardiovascular diagnostics and its dedication to supporting thescientific community. The company is excited to collaborate withleading experts and thought leaders at the conference and play a rolein improving research and patient outcomes.

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.

For further information, pleasecontact:

Jonathan Robinson

JRobinson@oakhillfinancial.ca

416-669-1001

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information

Company Name: Ventripoint Diagnostics Ltd.
Stock Symbol: VPT:CC
Market: TSXVC
Website: ventripoint.com

Menu

VPT:CC VPT:CC Quote VPT:CC Short VPT:CC News VPT:CC Articles VPT:CC Message Board
Get VPT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...